US Peptide Science Research Team
November 3, 2026
Between July and October 2026, the FDA documented significant safety failures in compounded glucagon-like peptide-1 (GLP-1) receptor agonist products. The FDA issued formal alerts regarding dosing errors associated with compounded injectable semaglutide. Simultaneously, multiple compounding facilities initiated recalls of peptide products, including Class I recalls involving glutathione products due to bacterial endotoxin contamination.
The most extensively documented facility failure involved Houston RX LLC, a 503A compounding pharmacy in Houston, Texas. Federal inspectors conducting a six-day inspection in August 2026 documented 14 observations of non-compliance with sterile compounding standards, resulting in a Class II recall of 64 vials of tirzepatide/niacinamide (20 mg/2 mg per mL) and 7 vials of sermorelin (1 mg/mL, 10 mL vials) medicaldaily.com.
Compounded injectable drugs bypass the skin's natural barrier, making contamination a direct pathway to serious infection. The Houston RX facility inspection revealed multiple critical sterility control failures:
Compounded products are not subject to FDA premarket review for safety, quality, or effectiveness. The Houston RX inspection documented that certificates for tirzepatide and semaglutide active ingredients were marked "research and development only," as were certificates for sermorelin and other ingredients labeled for "scientific research use." The niacinamide used in all GLP-1 formulas met dietary supplement standards rather than pharmaceutical standards, and several ingredients were stored at temperatures inconsistent with their labeled requirements medicaldaily.com.
Adverse events associated with compounded semaglutide dosing errors have been reported to include:
These events resulted from overdoses due to measurement confusion and calculation errors. Many individuals receiving compounded semaglutide vials lacked experience with self-injection techniques. Confusion between milliliters, milligrams, and "units" of measurement—combined with variable concentrations offered by different compounders—created high-risk conditions for dosing errors.
Compounded semaglutide products are often dispensed in multiple-dose vials with instructions to administer doses in "units"—a volume measurement whose actual milliliter equivalent varies depending on the product concentration. This creates a critical translation problem: a clinician or individual unfamiliar with the specific compounder's concentration may miscalculate dramatically. For example, if a syringe is sized for a dose that should be 0.5 mL but the individual receives a 3 mL syringe, the error margin is substantial.
A single compounder may offer multiple concentrations of the same drug. Without explicit, patient-facing labeling of concentration and clear syringe matching, individuals measuring from a vial into a syringe face ambiguity. The FDA has documented instances where individuals received syringes significantly larger than the prescribed volume, amplifying overdose risk.
Health care providers prescribing compounded semaglutide may not be aware of concentration variations available from the compounder. If a provider calculates a dose for one concentration but the compounder dispenses a different concentration, the resulting dose will be incorrect.
Research peptides intended for laboratory and in vitro research purposes operate under a different regulatory framework than compounded pharmaceutical products. Compounded pharmaceuticals are subject to FDA oversight under Section 503A of the Federal Food, Drug, and Cosmetic Act when distributed by state-licensed pharmacies, or Section 503B when produced by licensed outsourcing facilities. Research peptides sold explicitly for non-human research applications are not subject to the same compounding pharmacy regulations and are not intended for human therapeutic use. This distinction is critical for understanding the regulatory context of the 2026 recalls, which specifically target compounded drugs marketed or dispensed for human medical use.
The Houston RX LLC recall included the following lots:
Distribution was nationwide. Products matching these identifiers should not be used.
Compounded drugs do not undergo FDA premarket review for safety, quality, or effectiveness. This regulatory gap creates several inherent risks:
The FDA has stated that compounded drugs should only be used when medical needs cannot be met by an available FDA-approved drug.
Recalls are classified by the FDA based on health risk:
The Houston RX tirzepatide/niacinamide recall was classified as Class II, reflecting that use may cause temporary or medically reversible harm. However, the underlying sterility failures and ingredient sourcing issues documented in the FDA inspection represent serious manufacturing deficiencies medicaldaily.com.
The 2026 compounded GLP-1 recalls underscore the regulatory and manufacturing risks inherent in compounded pharmaceutical products. Documented failures in sterility assurance, ingredient sourcing, personnel hygiene, and environmental controls at major compounding facilities resulted in nationwide recalls and documented adverse events. The FDA's explicit guidance that compounded drugs should only be used when medical needs cannot be met by approved products reflects the higher risk profile of these preparations.
Key takeaways:
Source research
FDA Center for Drug Evaluation and Research